Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

2018 Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) Drug Analysis - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug analysis: Opdivo" drug pipelines has been added to ResearchAndMarkets.com's offering.

Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T cells.

PD-1 and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and B7 family. The B7 family cell surface molecules and the cytotoxic T-lymphocyte antigen 4 family both regulate complex signaling pathways that affect T-cell activation, tolerance, and immunopathology.

Blocking the interactions between PD-1 and its corresponding ligands prevents T-cell exhaustion in patients with cancer, allowing the T cells to combat the tumor via natural immune response mechanisms.

Product Profiles

  • Opdivo: Colorectal cancer (CRC)
  • Opdivo: Head and neck cancer
  • Opdivo: Hepatocellular carcinoma (HCC)
  • Opdivo: Bladder cancer
  • Opdivo: Glioblastoma (GBM)
  • Opdivo: Renal cell cancer (RCC)
  • Opdivo: Non-small cell lung cancer (NSCLC)
  • Opdivo: Gastric cancer
  • Opdivo: Melanoma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/sx5njt/2018_opdivo?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005849/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.